The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach

被引:11
作者
Chanthavilay, Phetsavanh [1 ,2 ]
Reinharz, Daniel [3 ,4 ]
Mayxay, Mayfong [1 ,5 ,6 ]
Phongsavan, Keokedthong [7 ]
Marsden, Donald E. [7 ]
Moore, Lynne [3 ]
White, Lisa J. [2 ,8 ]
机构
[1] Univ Hlth Sci, Fac Postgrad Studies, Viangchan, Laos
[2] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, 420-6 Rajvithi Rd, Bangkok 10400, Thailand
[3] Univ Laval, Fac Med, Dept Social & Prevent Med, 1050 Ave Med, Quebec City, PQ G1V 0A6, Canada
[4] Inst Francophonie Med Trop, Viangchan, Laos
[5] Mahosot Hosp, Microbiol Lab, Lao Oxford Mahosot Hosp, Wellcome Trust Res Unit LOMWRU, Samsenthai Rd,POB 744, Viangchan, Laos
[6] Univ Oxford, Churchill Hosp, Ctr Trop Med & Global Hlth, Oxford, England
[7] Setthathirath Hosp, Gynecol Oncol Unit, POB 6088, Viangchan, Laos
[8] Univ Oxford, Nuffield Dept Med, Oxford, England
来源
BMC HEALTH SERVICES RESEARCH | 2016年 / 16卷
基金
英国惠康基金;
关键词
Economic evaluation; HPV vaccination; Cervical cancer; Lao PDR; COST-EFFECTIVENESS; GLOBAL BURDEN; COUNTRIES; VACCINES; OUTCOMES; DISEASE; HEALTH; IMPACT;
D O I
10.1186/s12913-016-1662-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Cervical cancer, a preventable disease, is the third leading cause of cancer morbidity and mortality in the Lao People's Democratic Republic (Lao PDR). Since many cervical cancers are linked to human papilloma virus (HPV) infection, vaccination against this virus may lead to a reduction in these types of cancer. The study described here is the first to compare the cost-effectiveness of different HPV vaccination options in Lao PDR. Methods: A dynamic compartment model was created. The model included routine screening activities already in place, as well as theoretical interventions that included a 10-year old girl-only vaccination programme combined with/without a 10-year old boy vaccination programme and/or a catch-up component. The simulation was run over 100 years. In base case analyses, we assumed 70 % vaccination coverage with lifelong protection and 100 % efficacy against HPV types 16/18. The outcomes of interest were the incremental cost per Disability-Adjusted Life Year (DALY) averted. Results: In base case analyses, according to the WHO definition of cost-effectiveness thresholds, vaccinating 10-year-old girls was very cost-effective. Adding a catch-up vaccination element for females aged 11-25 years was also very cost-effective, costing 1559 international dollars (I$) per DALY averted. Increasing the age limit of the catch-up vaccination component to 75 years old showed that this remained a cost-effective option (I$ 5840 per DALY averted). Adding a vaccination programme for 10-year-old boys was not found to be cost-effective unless a short time simulation (30 years or less) was considered, along with a catch-up vaccination component for both males and females. Conclusions: Adding a catch-up female vaccination component is more attractive than adding a 10-year-old boy vaccination component.
引用
收藏
页数:10
相关论文
共 29 条
  • [1] Adam I, 2003, MAKING CHOICES HLTH
  • [2] [Anonymous], 2001, MACR HLTH INV HLTH E
  • [3] [Anonymous], 2012, 6 GLOB M IMPL NEW UN
  • [4] [Anonymous], 2013, COMPREHENSIVE CERVIC
  • [5] [Anonymous], 2012, HLTH SERV DEL PROF
  • [6] [Anonymous], GDP PER CAP PPP CURR
  • [7] Hepatitis B virus in the Lao People's Democratic Republic: a cross sectional serosurvey in different cohorts
    Black, Antony P.
    Nouanthong, Phonethipsavanh
    Nanthavong, Naphavan
    Souvannaso, Chanthasone
    Vilivong, Keooudomphone
    Jutavijittum, Prapan
    Samountry, Bounthome
    Luetteke, Nina
    Huebschen, Judith M.
    Goossens, Sylvie
    Quet, Fabrice
    Buisson, Yves
    Muller, Claude P.
    [J]. BMC INFECTIOUS DISEASES, 2014, 14
  • [8] Current status of human papillomavirus vaccination
    Brotherton, Julia M. L.
    Ogilvie, Gina S.
    [J]. CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 399 - 404
  • [9] Bruni L, 2019, Summary Report 10 March 2023
  • [10] Bruni L., 2015, HUMAN PAPILLOMAVIRUS